Key facts
- Zhuiyuan Medical’s last known valuation is $31.6M (Feb 2026).
- It has raised $2.9M; the latest was Early Stage VC ($2.9M) in Feb 2026.
- Notable investors include Shanghai Zhangjiang Science & Technology Venture Capital, Huayi Capital, Shanghai Kinetic Medical, Shanghai Sanyou Medical, Yongkan Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Zhuiyuan Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhuiyuan Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhuiyuan Medical
Developer of innovative cell therapy products designed for the intervertebral disc in the medical field. The company offers innovative cell therapies based on fibroblasts, fibrocell human fibroblast injection in multiple dose groups, thereby meeting the clinical needs of patients with degenerative disc disease.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Zhuiyuan Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhuiyuan Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhuiyuan Medical in its N-PORT filings yet. We sweep new filings monthly.